About 2nd iPSC Summit 2022
The new era of cell therapy has well and truly arrived, with the iPSC field holding the power to set a trailblazing fire to the field as recent advances in reprogramming and differentiation have unveiled the potential to develop fully scalable, off-the-shelf cell lines which could reduce cost of goods and increase accessibility to patients.
As the iPSC field continues to grow, advance and harness excitement, the flagship 2nd iPSC-Derived Cell Therapies Summit is reuniting industry leaders to tackle the challenges impeding development. Join us in Boston this December to review the latest updates and innovations in the space over two days and two tracks of content, featuring case studies, presentations and panel discussions with the likes of Century Therapeutics, Healios K.K., Sana Biotechnology, Takeda and many more.
Explore approaches to boost safe gene-editing, approach regulatory affairs, turbocharge scale-up, optimize analytics and more to produce best-in-class therapies for immune-oncology and regenerative medicine.
The iPSC Summit provides a dedicated forum to voice challenges, collaborate and spark conversations with the community committed to advancing iPSC-derived therapies. Take home new learnings and key insights from your peers to create high-quality, scalable, and affordable therapies.
Join Your Peers To:
Connect and collaborate with the field to overcome developmental hurdles
Develop efficient differentiation and cell engineering protocol to produce efficacious products without genomic instability with Vita Therapeutics, Exacis Biotherapeutics and SQZ Biotech
Accelerate iPSC-specific analytical development to enhance cell characterization and set robust release criteria with Aspen Neuroscience and Sana Biotechnology
Develop scalable end-to-end manufacturing processes to successfully produce iPSC products on a clinical and commercial scale with HebeCell and University of Minnesota
Enhance iPSC therapy potency and persistence whilst guaranteeing safety and preventing immunogenicity with Sana Biotechnology and Cytovia Therapeutics
Who Will You Meet?
130+ industry experts dedicated to advancing all aspects of iPSC development from translation to analytics to manufacturing, as well as the pioneers working to create the next generation of iPSC-derived cell therapies
2021 Attendees Included:
"Novel therapeutics are urgently needed and iPSC sourcing provides a uniquely valuable platform on which to design and develop new cancer therapeutics. Sharing and understanding the technologic advances, challenges, and strategies will allow for improved investments and approaches"
Stanley Frankel, CMO, Cytovia Therapeutics